Peptide-drug conjugates: A new paradigm for targeted cancer therapy
M Wang, J Liu, M Xia, L Yin, L Zhang, X Liu… - European Journal of …, 2024 - Elsevier
Peptide-drug conjugates (PDCs) are the new hope for targeted therapy after antibody-drug
conjugates (ADCs). Compared with ADCs, the core advantages of PDCs are enhanced …
conjugates (ADCs). Compared with ADCs, the core advantages of PDCs are enhanced …
[HTML][HTML] Electrochemical separation and purification of no-carrier-added 177Lu for radiopharmaceutical preparation: Translation from bench to bed
The entry of no-carrier-added (NCA) 177 Lu in the arena of clinical nuclear medicine has
revolutionized the practice of targeted radionuclide tumor therapy. In this study, we report the …
revolutionized the practice of targeted radionuclide tumor therapy. In this study, we report the …
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real …
Objectives: This study aimed to evaluate the clinical outcomes, including progression-free
survival (PFS), overall survival (OS), Objective Response Rate (ORR), and Disease Control …
survival (PFS), overall survival (OS), Objective Response Rate (ORR), and Disease Control …